How do weight-loss drugs like Mounjaro and Wegovy work?

• Key Takeaways on Weight-Loss Drugs
• Wegovy and Mounjaro are now accessible via NHS provision for eligible patients, alongside private availability, expanding treatment options for obesity management in UK practice
• Both medications work as GLP-1 receptor agonists, mimicking glucagon-like peptide-1 to regulate appetite and blood glucose—understanding their mechanism is essential for appropriate patient selection and counselling
• Clinicians should be aware of eligibility criteria, potential side effects, and the importance of lifestyle modification alongside pharmacotherapy when considering these agents for eligible patients

Wegovy and Mounjaro are available to certain patients on the NHS, and can also be bought privately.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.